Trial Profile
A Multicenter, Open-label Study to Assess the Long-term Safety, Tolerability, and Efficacy of Evolocumab (AMG145) on LDL-C in Subjects With Severe Familial Hypercholesterolemia
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 23 Dec 2021
Price :
$35
*
At a glance
- Drugs Evolocumab (Primary)
- Indications Hyperlipoproteinaemia type IIa
- Focus Adverse reactions; Registrational
- Acronyms PROFICIO; TAUSSIG
- Sponsors Amgen
- 18 Feb 2020 Results published in the Journal of the American College of Cardiology
- 29 May 2018 Status changed from active, no longer recruiting to completed.
- 30 Aug 2017 Results (n=14) presented at the ESC Congress 2017: Annual Congress of the European Society of Cardiology